87  Total SME IPOs listed in 2025

3,963.65 Crs.  Total funds raised in 2025

60  SME IPOs listed with Gain in 2025

27  SME IPOs listed with loss in 2025

87  Total SME IPOs listed in 2025

3963.65 Crs.  Total funds raised in 2025

60  SME IPOs listed with Gain in 2025

27  SME IPOs listed with loss in 2025

87  Total SME IPOs listed in 2025

3963.65 Crs.  Total funds raised in 2025

60  SME IPOs listed with Gain in 2025

27  SME IPOs listed with loss in 2025

87  Total SME IPOs listed in 2025

3963.65 Crs.  Total funds raised in 2025

60  SME IPOs listed with Gain in 2025

27  SME IPOs listed with loss in 2025

Mankind Pharma Limited IPO Analysis

Mankind Pharma IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ 4326.36 Cr. The company is based in New Delhi and caters to Pharmaceutical sector. Axis Capital , IIFL Securities , Jefferies India , Kotak Mahindra Capital Company are the merchant bankers of Mankind Pharma IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 15th September 2022.

Mankind Pharma IPO posted revenues of ₹ 9037.09 crores and PAT of ₹ 1346.92 crores in FY23 on annualised basis.

IPO Key Highlights

*At the time of IPO, on Annualised Basis
  • Revenue: ₹ 8.00 Cr.
            EBITDA: ₹ 1,991.47 Cr.
            PAT: ₹ 1.33 Cr.
  • EBITDA Margin: 24,893.33 %
            Pat Margin: 16.67 %
  • Net Worth: ₹ 7.00 Cr.
  • Market Capitalisation: ₹ 43263.60 Cr.
  • P/E: [●]
  • P/BV: 9.98 times
  • EV/EBITDA: 21.63 times
Nature of IPO : MainBoard
Exchange : BSE,NSE
IPO Type : Book Building

Mankind Pharma IPO Financial Performance (Restated)

Financial results of Mankind Pharma IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.

Amount in ₹ crores
Financials Dec-22 FY 22 FY 21 FY 20
Balance Sheet
Assets 9.00 9.00 6.00 5073.29
Net Worth 7.00 6.00 4.00 3.00
Total Debt 167.93 868.03 234.53 126.92
Profit & Loss
Revenue
Revenue on annualised basis
6.00
8.00
7.00 6.00 5.00
EBITDA
EBITDA on annualised basis
1493.60
1,991.47
2003.80 1659.70 1448.30
PAT
PAT on annualised basis
1.00
1.33
1.00 1.00 1.00
Financials
31-Dec-22
FY 22
FY 21
FY 20
Balance Sheet
Assets
9.00
9.00
6.00
5073.29

Net Worth
7.00
6.00
4.00
3.00

Total Debt
167.93
868.03
234.53
126.92

Profit & Loss
Revenue
Revenue on annualised basis
6.00
8.00
7.00
6.00
5.00

EBITDA
EBITDA on annualised basis
1493.60
1,991.47
2003.80
1659.70
1448.30

PAT
PAT on annualised basis
1.00
1.33
1.00
1.00
1.00

Notes:
1) Total debt incluides long-term borrowings and short-term borrowings.
2) Revenue means the Revenue from Operations as appearing in the Restated Financial Statements.

Mankind Pharma IPO Key performance Indicators (KPI)

Mankind Pharma IPO PAT Margin is 16.67 % , ROCE (Return on Capital Employed) is 16.58 % as per latest financial. The below table shows Mankind Pharma IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.

Particulars Dec-22 FY 22 FY 21 FY 20
EBITDA Margin (%) 24,893.33 28,625.71 27,661.67 28,966.00
PAT Margin (%) 16.67 14.29 16.67 20.00
EPS (₹) 24.87 35.78 31.59 25.72
ROE (%) 14.29 16.67 25.00 33.33
ROCE (%) 16.58 25.50 30.41 35.86
ROA (%) 11.11 11.11 16.67 0.02
Debt to Equity 23.99 144.67 58.63 42.31
Particulars
31-Dec-22
FY 22
FY 21
FY 20

EBITDA Margin (%)
24,893.33
28,625.71
27,661.67
28,966.00

PAT Margin (%)
16.67
14.29
16.67
20.00

EPS (₹)
24.87
35.78
31.59
25.72

ROE (%)
14.29
16.67
25.00
33.33

ROCE (%)
16.58
25.50
30.41
35.86

ROA (%)
11.11
11.11
16.67
0.02

Debt to Equity (x)  
23.99
144.67
58.63
42.31

Notes:
1) The EPS represents post-bonus basic EPS.
2) Return on Equity is ratio of Profit after Tax and Total Equity.
3) Return on Assets is ratio of Profit after Tax and Total Assets.
4) Debt to Equity is ratio of Total borrowings and Total Equity.

Mankind Pharma IPO Valuation Metrics

The market Capitalisation of Mankind Pharma IPO is ₹ 43263.60 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.

Key Metrics (at the time of IPO)


Market Capitalisation (₹ Cr.):
43263.60

Enterprise Value (EV) (₹ Cr.):
43,069.03

EV/EBITDA (times) :
21.63

PE Multiple (times) :
0.00

P/B (times) :
9.98

NAV (₹) :
178.38

Notes:
1) The Enterprise Value is calculated as Market Cap. + Total Debt - Cash and Cash Equivalents.
2) Price to Book multiple is calculated as the ratio of Market Cap. and Net Worth post IPO proceeds.

What are the key financial metrics in Mankind Pharma prospectus?

The Mankind Pharma IPO prospectus highlights an Return on Equity (ROE) of 14.29 % , Return on Assets (ROA) of 11.11 %, and an EBITDA Margin of 24,893.33 %, showcasing financial performance.

How do profitability ratios impact the evaluation of Mankind Pharma IPO?

Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Mankind Pharma IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.

What is the market capitalisation for Mankind Pharma IPO ?

The post-IPO market capitalisation of Mankind Pharma IPO is ₹ 43263.60 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.

What is the PE Multiple of Mankind Pharma IPO?

The Mankind Pharma IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.

What is the Revenue of Mankind Pharma IPO?

Mankind Pharma IPO reported revenue of ₹ 9037.09 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Mankind Pharma IPO provide insights into sales growth, market demand, and business scalability.

What is the EBITDA of Mankind Pharma IPO?

Mankind Pharma recorded an EBITDA of ₹ 1,991.47 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.

What is the PAT of Mankind Pharma IPO?

Mankind Pharma Profit After Tax (PAT) is ₹ 1.33 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions

IPO Key Highlights

*At the time of IPO, on Annualised Basis
  • Revenue: ₹ 8.00 Cr.
            EBITDA: ₹ 1,991.47 Cr.
            PAT: ₹ 1.33 Cr.
  • EBITDA Margin: 24,893.33 %
            Pat Margin: 16.67 %
  • Net Worth: ₹ 7.00 Cr.
  • Market Capitalisation: ₹ 43263.60 Cr.
  • P/E: [●]
  • P/BV: 9.98 times
  • EV/EBITDA: 21.63 times

Revenue

(As Annualised)

EBITDA

(As Annualised)

PAT

(As Annualised)
Thinking of
Listing Your Business through
SME IPO?
We can Help!
Contact Us Today

Recent IPO List

Aris Infra Solutions Limited

  Infrastructure

  Mumbai


Oswal Pumps Limited

  Solar

  Karnal


Scoda Tubes Limited

  Steel

  Ahmedabad


Prostarm Info Systems Limited

  Power and Energy

  Mumbai


Aegis Vopak Terminals Limited

  Oil and Gas

  Surat


Peer Companies Of This Sector

FAQs

Mankind Pharma operates in Pharmaceutical and Pharmaceutical Products With A Major Focus On Domestic Markets. The Issue is listed on BSE,NSE in May, 2023. Mankind Pharma IPO size was 4326.36 with Issue price of 1080.00 .

Merchant Banker(s) of Mankind Pharma IPO: Axis Capital Limited , IIFL Securities Limited , Jefferies India Private Limited , Kotak Mahindra Capital Company Limited

Mankind Pharma IPO subscription was 15.32 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.

Mankind Pharma IPO listed at a listing price of 1424.05 against the offer price of 1080.00.

The current market price of Mankind Pharma is 2303.50.

Services

IPO Advisory
IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Readiness
IPO Readiness
IPO Roadmap by improving Business Efficiencies, Financial Parameters and Corporate Structure to become IPO ready.
Fund Raising
Fund Raising
Fuelling a company's growth through Pre IPO Fund Raise, Private Equity, and Angel Investing.
SME : Business Scaling
SME Business Upscaling
Provide support to build a scalable SME business by unleashing the SME potential.
Post IPO Montoring
Post IPO Mentoring
Assisting with post IPO regulatory requirements and Performance Monitoring to achieve the milestone of Mainboard migration.

Thinking of
Listing Your Business through SME IPO?

We can help! Contact Us

Why Us?

  • Leading portal for IPOs
  • End to End Solutions
  • Known for Transparency